Founder-led clinical technology business providing proprietary eCOA/ePRO and real-time data monitoring solutions to pharmaceutical sponsors and CROs globally. Established in 1999, the company has delivered consistent profitability for over 30 years and operates entirely without external debt. The platform has been deployed across multi-centre trials in 60+ countries and is recognised for its precision, regulatory compliance and specialist autoimmune scoring capability.
Investment Highlights
• Consistently profitable, cash-generative business
• Debt-free, organically grown
• Proprietary SaaS platform with validated IP
• High barriers to entry in complex autoimmune assessments
• Global footprint (60+ countries)
• Scalable infrastructure with limited incremental cost
• Clear cross-therapeutic expansion potential
Platform & Differentiation
Secure, centrally configurable SaaS system enabling:
• Real-time eCRF / eCOA / ePRO data capture
• Automated validation and complex scoring algorithms
• Integrated data cleansing and adjudication
• Live trial monitoring dashboards
• Seamless integration with sponsor and CRO systems
• Multi-language deployment
The platform is the only system validated and recommended by the original authors of the BILAG disease activity index, positioning it as a reference-standard solution in complex autoimmune trials.
With defensible scoring IP, deep immunology expertise and scalable, therapy-agnostic infrastructure, the company represents a compelling strategic acquisition for CROs, eCOA providers, pharmaceutical sponsors and healthtech platforms seeking regulated clinical technology capability.
This is a rare opportunity to acquire a profitable, founder-led clinical SaaS asset with defensible IP, global deployment credentials and substantial growth optionality. Further information available upon execution of NDA.
